NYSEAMERICAN:ASXC Asensus Surgical Q4 2023 Earnings Report $0.35 0.00 (0.00%) As of 08/22/2024 Earnings HistoryForecast Asensus Surgical EPS ResultsActual EPS-$0.07Consensus EPS -$0.05Beat/MissMissed by -$0.02One Year Ago EPSN/AAsensus Surgical Revenue ResultsActual Revenue$5.43 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAsensus Surgical Announcement DetailsQuarterQ4 2023Date3/21/2024TimeN/AConference Call DateThursday, March 21, 2024Conference Call Time4:30PM ETConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Asensus Surgical Q4 2023 Earnings Call TranscriptProvided by QuartrMarch 21, 2024 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:00Good afternoon, ladies and gentlemen, and welcome to the Ascensus Surgical, Inc. 4th Quarter and Full Year 2023 Financial and Operating Results Conference Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Thursday, March 21, 2024. Operator00:00:32I would now like to turn the conference over to Mark Klausner from Westwicke Partners. Please go ahead. Speaker 100:00:40Good afternoon, everyone, and thank you for joining us for the Ascensus Surgical 4th quarter and full year 2023 business and financial update conference call. On the call with me today are Anthony Fernando, President and Chief Executive Officer and Shmise Rambertab, Chief Financial Officer. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call, including any guidance provided, are forward looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by our forward looking statements due to risks and uncertainties associated with the company's business, including any geopolitical factors beyond our control. The company undertakes no obligation to update the information provided on this call. Speaker 100:01:33For a discussion of risks and uncertainties associated with the Ascensus Surgical business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the 2023 Form 10 ks expected to be filed today and any other filings we make with the SEC. During this call, we will also present certain non GAAP financial information related to adjusted net loss attributable to common stockholders and the adjusted net loss per common share attributable to common stockholders. Management believes that these non GAAP financial measures taken in conjunction with U. S. GAAP financial measures provide useful information for both management and investors by excluding certain non cash and other expenses that are not indicative of the company's core operating results. Speaker 100:02:22Management uses non GAAP financial measures to compare our performance relative to forecast and strategic plans, the benchmark outperformance against competitors and for certain compensation decisions. Reconciliations from U. S. GAAP to non GAAP results are presented in the tables accompanying our earnings release, which can be found in the Investor Relations section of our website. With that, it's my pleasure to turn the call over to Ascensus Surgical's President and Chief Executive Officer, Anthony Fernando. Speaker 200:02:52Thanks, Mark, and thank you all for being with us today. To start, I'll give a summary of our recent performance and notable accomplishments in 2023. Then Shamish will dive into our financial results. Following that, I'll discuss our focus areas for 2024. And finally, we'll open the floor for any questions you may have. Speaker 200:03:16I'm pleased with the progress we've made throughout 2023 and the solid foundation we've built for the future. We continue to drive greater adoption and utilization of both Senhance and the ISU, while at the same time making significant progress towards the development of our next generation Luna Surgical system. Growing procedure volumes remains critical factor as we seek to refine and enhance our digital surgery capabilities. Globally, over 3,550 procedures were performed using the Senhance system in 2023, delivering 13% increase from 2022. During the Q4, we saw over 8.35 Senhance procedures performed across a variety of specialties globally. Speaker 200:04:12As we continue to gather surgical data, our machine learning engine improves, enabling us to provide valuable clinical insights to surgeons through the ISU. A testament to this, last month, we announced the completion of more than 1,000 successful cases each at 3 hospitals, Evangelasis Krankenhaus Wesel in Germany, Klaipeda University Hospital in Lithuania and Presidential Clinic Astana in the CIS region. Another encouraging trend we've observed is at Ida Oberstein Hospital, where in just 4 months since the program's initiation in November 2023, they have completed over 110 cases. These achievements underscore the growing acceptance and confidence in Senhance and how our customers are realizing the value Senhance brings to the OR. Due to the increased procedure volumes, our TRUST registry now includes data from over 3,200 patients with a growing number of cases, which has been aided by the continued expansion of sites participating in the registry. Speaker 200:05:34Additionally, during the year, 9 peer reviewed clinical publications were published, including a paper exploring surgeon stress levels using Senhance. Led by trust investigators, this study compared stress levels between surgeons using Senhance and traditional laparoscopic surgery. After analyzing 350 procedures, the research found that Senhance users experienced lower overall stress levels compared to laparoscopic surgeons due to reduced physical demands and distractions during procedures. Moving to new program initiations, we initiated 5 new Senhance programs in the 4th quarter, including 1 in Germany, 1 in Romania, 2 in the CIS region and 1 in Japan at Nagoya University Hospital, bringing the total for the year to 8. One of these program initiations was a pediatric hospital in Romania, representing the 6th hospital to be leveraging the Senhance for pediatric procedures. Speaker 200:06:49With specialized 3 millimeter and 5 millimeter instruments, the Senhance surgical system is uniquely designed for the delicate nature of pediatric procedures. As more pediatric surgeons recognize a sensor's unique system design, which not only preserves minimally invasive surgery, but also advances laparoscopy and robotics with digital surgery solutions. We expect interest in Senhance and the ISU for pediatric applications to continue to grow. We are committed to meeting this rising demand in the pediatric market. To wrap up, I'm pleased with the progress we've achieved in the 4th quarter and continue to build on the groundwork for sustained success. Speaker 200:07:44I'll now pass the floor to Sameer for a financial update. Speaker 300:07:48Thanks, Anthony. Turning to the Q4. For the 3 months ended December 31, 2023, the company reported revenue of $5,400,000 as compared to revenue of $2,500,000 in the 3 months ended December 31, 2022. Revenue in the Q4 of 2023 included $3,600,000 in system revenue, dollars 1,000,000 in instruments and accessories, dollars 500,000 in lease revenues and $300,000 in services. For the 3 months ended December 31, 2023, total operating expenses were $17,200,000 as compared to $18,300,000 in the 3 months ended December 31, 2022. Speaker 300:08:39For the 3 months ended December 31, 2023, net loss attributable to common stockholders was $17,200,000 or $0.07 per share as compared to a net loss attributable to common stockholders of $17,900,000 or $0.08 per share in the 3 months ended December 31, 2022. For the 3 months ended December 31, 2023, the adjusted net loss attributable to common stockholders was $17,500,000 or $0.07 per share as compared to an adjusted net loss of $16,700,000 or $0.07 per share in the 3 months ended December 31, 2022. Adjusted net loss is GAAP net loss adjusted for the following items, amortization of intangible assets, change in fair value of contingent consideration, property and equipment impairment and change in fair value of warrant liabilities, all of which are non cash charges. Adjusted net loss attributable to common stockholders is a non GAAP financial measure. Reconciliation from GAAP to non GAAP measures can be found in our earnings release. Speaker 300:09:53Turning to the balance sheet. The company had cash, cash equivalents and short term investments, excluding restricted cash of approximately $21,100,000 as of December 31, 2023. In the Q3 of 2023, we initiated a cash burn reduction plan to streamline expenses. As a result of the plan, we saw a cash burn decrease in the Q4 and into the Q1. Based on the recent financing and our current operating plan, we project that available cash will now sustain operations until early June 2024. Speaker 300:10:29I'll turn the call back over to Anthony. Speaker 200:10:32Thanks, Shamesh. We wanted to provide an update on what lies ahead at Ascensus in 2024. Starting with Luna, in December, we hosted a surgeon lab in Research Triangle Park, North Carolina to conduct an in vivo evaluation of Luna's hardware, software and instruments in POSEEM models. The lab allowed 9 participating surgeons to evaluate the system's functionality in 13 different procedures across gynecology, urology and general surgery. The surgeon lab highlighted Luna's notable range of motion and instrument dexterity essential for precise surgical maneuvers. Speaker 200:11:19Surgeons also appreciated the strength and reliability of the 5 millimeter TruWrist instrument line offering versatility with different instrument types. Additionally, they found the ergonomic design of the Luna Surgeon console and easy patient access to be noteworthy features. The positive feedback from participating surgeons underscores our dedication to developing and delivering a surgical robotic platform that exceeds expectations. Insights gathered during this evaluation will aid in refining the system design, bringing us closer to a final product. For a closer look at the surgeon lab and insights from the participating surgeons, a video is available on our Investor Relations website. Speaker 200:12:11The video provides an overview of the Luna system features demonstrating its range of motion, instrument strength and ergonomic benefits. In order to conserve capital, we are adjusting our development timeline. This decision allows us to maintain physical stability while still advancing towards key milestones for Luna. We now intend to freeze the systems design in Q3 2024 and conduct verification and validation testing in Q4 2024. Subsequently, we will initiate pilot manufacturing and prepare for regulatory submissions. Speaker 200:12:53The submission is now expected in the second half of twenty twenty five with clearance anticipated in the first half of twenty twenty six, followed by a launch thereafter. As we have shared before, we are following a clear and defined regulatory pathway for Luna, Drawing from our interactions with the FDA and our proven success in submission for Senhance, we anticipate following a traditional 510 pathway in the U. S. Rather than the more rigorous, the Nova pathway, which we believe will save both time and costs. Additionally, we have some important Lunar Digital Solutions milestones to highlight in the near term. Speaker 200:13:41By Q2 2024, we aim to integrate several new features into our digital platform, including advanced analytical tools with multi point and plane measurement functions, innovative training and communication tools with telestration capabilities and enhanced safety features. Furthermore, we are striving to conduct prototype testing for our digital features within the same timeframe. Surgeon advisors will give us valuable feedback on functionality and user experience, helping us ensure that our digital solutions are user friendly and effective. In parallel, we are planning to launch our customer portal website globally during Q2 2024. This platform will be accessible to all Senhance users with a sensor's cloud connectivity, providing useful resources like procedure specific data, statistics and downloadable or shareable videos. Speaker 200:14:46It is a significant step forward in improving collaboration and accessibility within our user community. Turning to our ongoing ISU development efforts, our primary goal for the year is to ramp up manufacturing for the future ISU hardware with our partners. Additionally, we are working on completing the design for 2 ISU configurations and expect that we will be finalizing the hardware by the Q2 of 2024. These configurations include the Luna ISU, which supports a robotic platform configuration and the standalone ISU aimed at enhancing laparoscopic procedures. These configurations will offer flexibility and efficiency to meet various surgical needs and preferences. Speaker 200:15:40Regarding Senhance initiation, we intend to initiate 8 to 10 new programs in 2024. Additionally, we expect procedure volume growth for 2024 to track close to 15% to 20% growth over 2023. The data gathered from the Trust Registry during these procedures has been immensely valuable and with the adoption of the ISU by more sites in the coming months, our data pool will expand further. This data collection from the Trust Registry and independent studies plays a vital role in bridging, Senhance and Luna. Additionally, we aim to enhance our cloud data architecture, leveraging Google Cloud's advanced technologies to provide surgeons with real time intraoperative clinical intelligence. Speaker 200:16:36This initiative has the potential to achieve superior outcomes for patients. Looking ahead to 2024, we are optimistic about reaching important milestones in the coming quarters. Our Luna Surgical system remains our primary focus in the year. Additionally, we are dedicated to expanding Senhance adoption, increasing utilization, advancing clinical evidence and enhancing our digital capabilities. We sincerely appreciate the hard work and dedication of our global team in bringing these innovations to life, underscoring our commitment to advancing surgery technology and improving patient outcomes. Speaker 200:17:22With that, we would now like to open the line for questions. Operator00:17:29Thank you. Ladies and gentlemen, we will now conduct the question and answer session. Your first question comes from Ross Osborne from Cantor Fitzgerald. Your line is now open. Speaker 400:17:59Hey guys, thanks for taking the questions. And I apologize for the background noise traveling today. But starting off, would you walk through your thoughts around financing in terms of size and structure to keep the company going past June? And then as a follow-up, where were you able to cut costs during the Q4? And has burn improved during the Q1? Speaker 200:18:23Hi, Ross. Thanks for the question. I think as we noted on the cash, we kind of ended the Q4 with $21,000,000 in cash. And obviously for capital raise and cash, we are exploring several options, including equity, non dilutive transactions, licensing agreements. And we will look to execute something, obviously, that's in the best interest of the company and the shareholders. Speaker 200:18:59That's kind of the plan. Then on the cost, I think it came out from several areas, some on the R and D front, which is why we had to shift the timelines for Luna Development and also from all the other functions. So it was across the company streamlining of expenses and our planned budgets. Speaker 400:19:32Okay, understood. And then just one more question, if I may. Assuming financing comes through as needed, the story is obviously going to be about Luna at that point. How much capital do you think you'll need to raise to successfully develop and then commercialize Luna, especially given the cuts over the past couple of quarters? Speaker 200:19:56Ross, I think you can kind of work through the burn, right? I mean, based on what we've done before previous quarters and that's the trajectory that we need to continue to intersect with the timelines that we have outlined. So I think we have the right we have the team in place and then we've been doing all the right things to get to where we need to and now it's just a matter of time purely for execution. So I'm sure you can work up the numbers based on historical burn and that will continue through to regulatory approval. Operator00:20:48Your next question comes from RK Ramakanth from H. C. Wainwright. Your line is now open. Speaker 500:20:57Thank you. Good afternoon, Anthony and Shamiz. So looking at your past history and how you've been able to add new initiations year after year. Have you understood how the market is working for you in the sense because you come up you certainly managed to get your 8 to 10 initiations, but in terms of trying to get better than that, what needs to be done? And also how are you thinking of managing the growth of the procedure volumes as well? Speaker 200:21:54Okay. Thank you for the question. So I'll take the 2 parts, take the latter part first. With respect to procedures, I mean, some of the sites are mature sites that have seen the benefit of Senhance in terms of efficiency and cost and familiarity with laparoscopy and their training. So that is driving increased usage at some of the mature sites. Speaker 200:22:23And then some of the newer sites have seen this, and they are trying to mimic that kind of performance. And obviously, over the years, we've also gained a significant amount of experience about how best to stand up a site and drive volume at a specific site efficiently. So all of that's kind of playing through quite nicely for us to continue to grow utilization. And like I've said before, if we look at the trend of utilization on a per system basis globally, that has been increasing year after year after year. So it's not just the new systems doing more cases. Speaker 200:23:11So that's one part. And the second part, driving Senan's adoption in terms of systems, I mean, pediatrics has been helping us quite a bit because we are seeing a really good interest in pediatrics in Japan, in Europe and even in the U. S. Like last year, this time we had maybe 1 or 2 pediatric sites, now we are up to 6 and we anticipate that to continue to grow. And also the other sites that are working with us, they do they have they want economics to be responsible in terms of procedure costs and where there is a priority for cost. Speaker 200:24:02Obviously, we have a proven track record there. So we kind of are able to work together. So those are the 2 things I would say that we continue to be able to do that and obviously to continue to grow beyond that once we get further ahead. Speaker 500:24:23Okay. Thank you for that. And then in terms of the ISU and trying to come up with these 2 novel configurations. So how I'm just trying to understand what's the development timeline on this and how do you plan to commercialize this at the end of the day? Speaker 200:24:52Yes. Okay. So the 2 configurations, obviously, we have the 1st generation ISU on the market today and we are in the process of developing the 2nd generation ISU. And one version of that will be part of Luna, that is the robotic version of the ISU. So it will have all some of the features that we currently have and continue to evolve in terms of performance, features, applications, so on that are related to robotic platform, robotic manipulation. Speaker 200:25:27The second version of the new ISU primarily for standalone use, for use on laparoscopy without a robot. So we have seen interest in that area and we are going to continue to build some of the applications that are relative and relevant to non robotic surgery. And as for commercialization, I think there are multiple ways that and again, several options are being explored. Do we do it ourselves and other partnership opportunities for us to leverage other commercial infrastructure to be able to gain adoption. So that's the commercial part say exploratory, but we know there is a need for this and we have the clear regulatory pathway and also the features relatively well developed. Speaker 200:26:31So that's the reason why we decided that we're going to go down 2 path ways and be able to offer this not only for robotic, but also standalone news. Speaker 500:26:41Okay. Thanks. Thank you for taking my questions. Speaker 200:26:45Thank you, RK. Operator00:26:51There are no further questions at this time. Mr. Anthony Fernando, please proceed. Speaker 200:26:57Thank you, operator. Thank you, everyone, for joining today's call, and we look forward to updating you on our progress throughout the year. Operator00:27:09Ladies and gentlemen, this concludes today's conference call. Thank you for joining. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallAsensus Surgical Q4 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Annual report(10-K) Asensus Surgical Earnings HeadlinesAsensus Surgical Announces Closing of Acquisition by KARL STORZAugust 22, 2024 | globenewswire.comDurham public company staves off potential bankruptcy, will be acquiredAugust 21, 2024 | bizjournals.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.April 25, 2025 | Altimetry (Ad)Durham company could face bankruptcy if $95M sale failsAugust 15, 2024 | bizjournals.comBiggest stock movers today: NU, K, and moreAugust 14, 2024 | msn.comAsensus says it expects to file for bankruptcy if merger vote failsAugust 13, 2024 | msn.comSee More Asensus Surgical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Asensus Surgical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Asensus Surgical and other key companies, straight to your email. Email Address About Asensus SurgicalAsensus Surgical (NYSEAMERICAN:ASXC), a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.View Asensus Surgical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step In Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Booking (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:00Good afternoon, ladies and gentlemen, and welcome to the Ascensus Surgical, Inc. 4th Quarter and Full Year 2023 Financial and Operating Results Conference Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Thursday, March 21, 2024. Operator00:00:32I would now like to turn the conference over to Mark Klausner from Westwicke Partners. Please go ahead. Speaker 100:00:40Good afternoon, everyone, and thank you for joining us for the Ascensus Surgical 4th quarter and full year 2023 business and financial update conference call. On the call with me today are Anthony Fernando, President and Chief Executive Officer and Shmise Rambertab, Chief Financial Officer. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call, including any guidance provided, are forward looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by our forward looking statements due to risks and uncertainties associated with the company's business, including any geopolitical factors beyond our control. The company undertakes no obligation to update the information provided on this call. Speaker 100:01:33For a discussion of risks and uncertainties associated with the Ascensus Surgical business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the 2023 Form 10 ks expected to be filed today and any other filings we make with the SEC. During this call, we will also present certain non GAAP financial information related to adjusted net loss attributable to common stockholders and the adjusted net loss per common share attributable to common stockholders. Management believes that these non GAAP financial measures taken in conjunction with U. S. GAAP financial measures provide useful information for both management and investors by excluding certain non cash and other expenses that are not indicative of the company's core operating results. Speaker 100:02:22Management uses non GAAP financial measures to compare our performance relative to forecast and strategic plans, the benchmark outperformance against competitors and for certain compensation decisions. Reconciliations from U. S. GAAP to non GAAP results are presented in the tables accompanying our earnings release, which can be found in the Investor Relations section of our website. With that, it's my pleasure to turn the call over to Ascensus Surgical's President and Chief Executive Officer, Anthony Fernando. Speaker 200:02:52Thanks, Mark, and thank you all for being with us today. To start, I'll give a summary of our recent performance and notable accomplishments in 2023. Then Shamish will dive into our financial results. Following that, I'll discuss our focus areas for 2024. And finally, we'll open the floor for any questions you may have. Speaker 200:03:16I'm pleased with the progress we've made throughout 2023 and the solid foundation we've built for the future. We continue to drive greater adoption and utilization of both Senhance and the ISU, while at the same time making significant progress towards the development of our next generation Luna Surgical system. Growing procedure volumes remains critical factor as we seek to refine and enhance our digital surgery capabilities. Globally, over 3,550 procedures were performed using the Senhance system in 2023, delivering 13% increase from 2022. During the Q4, we saw over 8.35 Senhance procedures performed across a variety of specialties globally. Speaker 200:04:12As we continue to gather surgical data, our machine learning engine improves, enabling us to provide valuable clinical insights to surgeons through the ISU. A testament to this, last month, we announced the completion of more than 1,000 successful cases each at 3 hospitals, Evangelasis Krankenhaus Wesel in Germany, Klaipeda University Hospital in Lithuania and Presidential Clinic Astana in the CIS region. Another encouraging trend we've observed is at Ida Oberstein Hospital, where in just 4 months since the program's initiation in November 2023, they have completed over 110 cases. These achievements underscore the growing acceptance and confidence in Senhance and how our customers are realizing the value Senhance brings to the OR. Due to the increased procedure volumes, our TRUST registry now includes data from over 3,200 patients with a growing number of cases, which has been aided by the continued expansion of sites participating in the registry. Speaker 200:05:34Additionally, during the year, 9 peer reviewed clinical publications were published, including a paper exploring surgeon stress levels using Senhance. Led by trust investigators, this study compared stress levels between surgeons using Senhance and traditional laparoscopic surgery. After analyzing 350 procedures, the research found that Senhance users experienced lower overall stress levels compared to laparoscopic surgeons due to reduced physical demands and distractions during procedures. Moving to new program initiations, we initiated 5 new Senhance programs in the 4th quarter, including 1 in Germany, 1 in Romania, 2 in the CIS region and 1 in Japan at Nagoya University Hospital, bringing the total for the year to 8. One of these program initiations was a pediatric hospital in Romania, representing the 6th hospital to be leveraging the Senhance for pediatric procedures. Speaker 200:06:49With specialized 3 millimeter and 5 millimeter instruments, the Senhance surgical system is uniquely designed for the delicate nature of pediatric procedures. As more pediatric surgeons recognize a sensor's unique system design, which not only preserves minimally invasive surgery, but also advances laparoscopy and robotics with digital surgery solutions. We expect interest in Senhance and the ISU for pediatric applications to continue to grow. We are committed to meeting this rising demand in the pediatric market. To wrap up, I'm pleased with the progress we've achieved in the 4th quarter and continue to build on the groundwork for sustained success. Speaker 200:07:44I'll now pass the floor to Sameer for a financial update. Speaker 300:07:48Thanks, Anthony. Turning to the Q4. For the 3 months ended December 31, 2023, the company reported revenue of $5,400,000 as compared to revenue of $2,500,000 in the 3 months ended December 31, 2022. Revenue in the Q4 of 2023 included $3,600,000 in system revenue, dollars 1,000,000 in instruments and accessories, dollars 500,000 in lease revenues and $300,000 in services. For the 3 months ended December 31, 2023, total operating expenses were $17,200,000 as compared to $18,300,000 in the 3 months ended December 31, 2022. Speaker 300:08:39For the 3 months ended December 31, 2023, net loss attributable to common stockholders was $17,200,000 or $0.07 per share as compared to a net loss attributable to common stockholders of $17,900,000 or $0.08 per share in the 3 months ended December 31, 2022. For the 3 months ended December 31, 2023, the adjusted net loss attributable to common stockholders was $17,500,000 or $0.07 per share as compared to an adjusted net loss of $16,700,000 or $0.07 per share in the 3 months ended December 31, 2022. Adjusted net loss is GAAP net loss adjusted for the following items, amortization of intangible assets, change in fair value of contingent consideration, property and equipment impairment and change in fair value of warrant liabilities, all of which are non cash charges. Adjusted net loss attributable to common stockholders is a non GAAP financial measure. Reconciliation from GAAP to non GAAP measures can be found in our earnings release. Speaker 300:09:53Turning to the balance sheet. The company had cash, cash equivalents and short term investments, excluding restricted cash of approximately $21,100,000 as of December 31, 2023. In the Q3 of 2023, we initiated a cash burn reduction plan to streamline expenses. As a result of the plan, we saw a cash burn decrease in the Q4 and into the Q1. Based on the recent financing and our current operating plan, we project that available cash will now sustain operations until early June 2024. Speaker 300:10:29I'll turn the call back over to Anthony. Speaker 200:10:32Thanks, Shamesh. We wanted to provide an update on what lies ahead at Ascensus in 2024. Starting with Luna, in December, we hosted a surgeon lab in Research Triangle Park, North Carolina to conduct an in vivo evaluation of Luna's hardware, software and instruments in POSEEM models. The lab allowed 9 participating surgeons to evaluate the system's functionality in 13 different procedures across gynecology, urology and general surgery. The surgeon lab highlighted Luna's notable range of motion and instrument dexterity essential for precise surgical maneuvers. Speaker 200:11:19Surgeons also appreciated the strength and reliability of the 5 millimeter TruWrist instrument line offering versatility with different instrument types. Additionally, they found the ergonomic design of the Luna Surgeon console and easy patient access to be noteworthy features. The positive feedback from participating surgeons underscores our dedication to developing and delivering a surgical robotic platform that exceeds expectations. Insights gathered during this evaluation will aid in refining the system design, bringing us closer to a final product. For a closer look at the surgeon lab and insights from the participating surgeons, a video is available on our Investor Relations website. Speaker 200:12:11The video provides an overview of the Luna system features demonstrating its range of motion, instrument strength and ergonomic benefits. In order to conserve capital, we are adjusting our development timeline. This decision allows us to maintain physical stability while still advancing towards key milestones for Luna. We now intend to freeze the systems design in Q3 2024 and conduct verification and validation testing in Q4 2024. Subsequently, we will initiate pilot manufacturing and prepare for regulatory submissions. Speaker 200:12:53The submission is now expected in the second half of twenty twenty five with clearance anticipated in the first half of twenty twenty six, followed by a launch thereafter. As we have shared before, we are following a clear and defined regulatory pathway for Luna, Drawing from our interactions with the FDA and our proven success in submission for Senhance, we anticipate following a traditional 510 pathway in the U. S. Rather than the more rigorous, the Nova pathway, which we believe will save both time and costs. Additionally, we have some important Lunar Digital Solutions milestones to highlight in the near term. Speaker 200:13:41By Q2 2024, we aim to integrate several new features into our digital platform, including advanced analytical tools with multi point and plane measurement functions, innovative training and communication tools with telestration capabilities and enhanced safety features. Furthermore, we are striving to conduct prototype testing for our digital features within the same timeframe. Surgeon advisors will give us valuable feedback on functionality and user experience, helping us ensure that our digital solutions are user friendly and effective. In parallel, we are planning to launch our customer portal website globally during Q2 2024. This platform will be accessible to all Senhance users with a sensor's cloud connectivity, providing useful resources like procedure specific data, statistics and downloadable or shareable videos. Speaker 200:14:46It is a significant step forward in improving collaboration and accessibility within our user community. Turning to our ongoing ISU development efforts, our primary goal for the year is to ramp up manufacturing for the future ISU hardware with our partners. Additionally, we are working on completing the design for 2 ISU configurations and expect that we will be finalizing the hardware by the Q2 of 2024. These configurations include the Luna ISU, which supports a robotic platform configuration and the standalone ISU aimed at enhancing laparoscopic procedures. These configurations will offer flexibility and efficiency to meet various surgical needs and preferences. Speaker 200:15:40Regarding Senhance initiation, we intend to initiate 8 to 10 new programs in 2024. Additionally, we expect procedure volume growth for 2024 to track close to 15% to 20% growth over 2023. The data gathered from the Trust Registry during these procedures has been immensely valuable and with the adoption of the ISU by more sites in the coming months, our data pool will expand further. This data collection from the Trust Registry and independent studies plays a vital role in bridging, Senhance and Luna. Additionally, we aim to enhance our cloud data architecture, leveraging Google Cloud's advanced technologies to provide surgeons with real time intraoperative clinical intelligence. Speaker 200:16:36This initiative has the potential to achieve superior outcomes for patients. Looking ahead to 2024, we are optimistic about reaching important milestones in the coming quarters. Our Luna Surgical system remains our primary focus in the year. Additionally, we are dedicated to expanding Senhance adoption, increasing utilization, advancing clinical evidence and enhancing our digital capabilities. We sincerely appreciate the hard work and dedication of our global team in bringing these innovations to life, underscoring our commitment to advancing surgery technology and improving patient outcomes. Speaker 200:17:22With that, we would now like to open the line for questions. Operator00:17:29Thank you. Ladies and gentlemen, we will now conduct the question and answer session. Your first question comes from Ross Osborne from Cantor Fitzgerald. Your line is now open. Speaker 400:17:59Hey guys, thanks for taking the questions. And I apologize for the background noise traveling today. But starting off, would you walk through your thoughts around financing in terms of size and structure to keep the company going past June? And then as a follow-up, where were you able to cut costs during the Q4? And has burn improved during the Q1? Speaker 200:18:23Hi, Ross. Thanks for the question. I think as we noted on the cash, we kind of ended the Q4 with $21,000,000 in cash. And obviously for capital raise and cash, we are exploring several options, including equity, non dilutive transactions, licensing agreements. And we will look to execute something, obviously, that's in the best interest of the company and the shareholders. Speaker 200:18:59That's kind of the plan. Then on the cost, I think it came out from several areas, some on the R and D front, which is why we had to shift the timelines for Luna Development and also from all the other functions. So it was across the company streamlining of expenses and our planned budgets. Speaker 400:19:32Okay, understood. And then just one more question, if I may. Assuming financing comes through as needed, the story is obviously going to be about Luna at that point. How much capital do you think you'll need to raise to successfully develop and then commercialize Luna, especially given the cuts over the past couple of quarters? Speaker 200:19:56Ross, I think you can kind of work through the burn, right? I mean, based on what we've done before previous quarters and that's the trajectory that we need to continue to intersect with the timelines that we have outlined. So I think we have the right we have the team in place and then we've been doing all the right things to get to where we need to and now it's just a matter of time purely for execution. So I'm sure you can work up the numbers based on historical burn and that will continue through to regulatory approval. Operator00:20:48Your next question comes from RK Ramakanth from H. C. Wainwright. Your line is now open. Speaker 500:20:57Thank you. Good afternoon, Anthony and Shamiz. So looking at your past history and how you've been able to add new initiations year after year. Have you understood how the market is working for you in the sense because you come up you certainly managed to get your 8 to 10 initiations, but in terms of trying to get better than that, what needs to be done? And also how are you thinking of managing the growth of the procedure volumes as well? Speaker 200:21:54Okay. Thank you for the question. So I'll take the 2 parts, take the latter part first. With respect to procedures, I mean, some of the sites are mature sites that have seen the benefit of Senhance in terms of efficiency and cost and familiarity with laparoscopy and their training. So that is driving increased usage at some of the mature sites. Speaker 200:22:23And then some of the newer sites have seen this, and they are trying to mimic that kind of performance. And obviously, over the years, we've also gained a significant amount of experience about how best to stand up a site and drive volume at a specific site efficiently. So all of that's kind of playing through quite nicely for us to continue to grow utilization. And like I've said before, if we look at the trend of utilization on a per system basis globally, that has been increasing year after year after year. So it's not just the new systems doing more cases. Speaker 200:23:11So that's one part. And the second part, driving Senan's adoption in terms of systems, I mean, pediatrics has been helping us quite a bit because we are seeing a really good interest in pediatrics in Japan, in Europe and even in the U. S. Like last year, this time we had maybe 1 or 2 pediatric sites, now we are up to 6 and we anticipate that to continue to grow. And also the other sites that are working with us, they do they have they want economics to be responsible in terms of procedure costs and where there is a priority for cost. Speaker 200:24:02Obviously, we have a proven track record there. So we kind of are able to work together. So those are the 2 things I would say that we continue to be able to do that and obviously to continue to grow beyond that once we get further ahead. Speaker 500:24:23Okay. Thank you for that. And then in terms of the ISU and trying to come up with these 2 novel configurations. So how I'm just trying to understand what's the development timeline on this and how do you plan to commercialize this at the end of the day? Speaker 200:24:52Yes. Okay. So the 2 configurations, obviously, we have the 1st generation ISU on the market today and we are in the process of developing the 2nd generation ISU. And one version of that will be part of Luna, that is the robotic version of the ISU. So it will have all some of the features that we currently have and continue to evolve in terms of performance, features, applications, so on that are related to robotic platform, robotic manipulation. Speaker 200:25:27The second version of the new ISU primarily for standalone use, for use on laparoscopy without a robot. So we have seen interest in that area and we are going to continue to build some of the applications that are relative and relevant to non robotic surgery. And as for commercialization, I think there are multiple ways that and again, several options are being explored. Do we do it ourselves and other partnership opportunities for us to leverage other commercial infrastructure to be able to gain adoption. So that's the commercial part say exploratory, but we know there is a need for this and we have the clear regulatory pathway and also the features relatively well developed. Speaker 200:26:31So that's the reason why we decided that we're going to go down 2 path ways and be able to offer this not only for robotic, but also standalone news. Speaker 500:26:41Okay. Thanks. Thank you for taking my questions. Speaker 200:26:45Thank you, RK. Operator00:26:51There are no further questions at this time. Mr. Anthony Fernando, please proceed. Speaker 200:26:57Thank you, operator. Thank you, everyone, for joining today's call, and we look forward to updating you on our progress throughout the year. Operator00:27:09Ladies and gentlemen, this concludes today's conference call. Thank you for joining. You may now disconnect.Read morePowered by